News Beckley psychedelic hits the target, unlocking atai merger The proposed merger between Beckley Psytech and atai can go ahead as a psychedelic for depression hits all its endpoints in a phase 2b trial.
News App to support people with depression launches in GB A smartphone app for depression developed by Otsuka and Click Therapeutics has been launched in Great Britain, its first European market.
News Welsh biotech Draig emerges with $140m in financing Draig Therapeutics emerged from the shadows this morning with $140m in funding and a quest to develop new therapies for neuropsychiatric diseases.
News Consolidation in psychedelics as atai pairs with Beckley Beckley Psytech has agreed to merge with atai Life Sciences in a deal that would bring together two psychedelic medicine pioneers.
News Beckley's psychedelic med inches forward in depression UK psychedelic medicines developer Beckley Psytech has said its candidate for treatment-resistant depression has enhanced the effect of standard antidepressants in a phase 2 trial.
News One of J&J's blockbuster depression hopes has flamed out Johnson & Johnson has halted the development of aticaprant as a treatment for major depressive disorder, blowing a hole in its late-stage pipeline.
News NICE relents and backs Kisqali for wide use in breast cancer Novartis' breast cancer therapy Kisqali has been cleared for NHS use in early breast cancer, an indication driving blockbuster sales of the drug.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face